MutationTaster and ESM-1b: Brandes et al. 2023 Supplementary Table 2: full benchmark evaluations of ESM1b and all other methods and An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers disagree
- Low severity
- Not yet reviewed
- two-study-conflict
- unknown
Brandes et al. 2023 Supplementary Table 2: full benchmark evaluations of ESM1b and all other methods ranks ESM-1b above MutationTaster in 4 of 4 comparisons; An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers ranks MutationTaster above ESM-1b in 5 of 5 comparisons. No other study gives a verdict, so neither is the outlier.
2 papers rank MutationTaster above ESM-1b in 5 of their 10 comparisons and ESM-1b higher in 4; 1 is a tie. Of those papers, Brandes et al. 2023 ranks ESM-1b higher on its own (4 of 4).
- Compared
- MutationTaster, ESM-1b
Not reviewed yet.